COMMUNIQUÉS West-GlobeNewswire

Zymeworks Announces Appointment of Dr. Alessandra Cesano to its Board of Directors
08/02/2024
VANCOUVER, British Columbia, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the [...]
Immuron CEO, Steven Lydeamore Investor Webinar Presentation
08/02/2024
MELBOURNE, Australia, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our Chief Executive Officer, [...]
BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs
08/02/2024
Strategic alliance leverages manufacturing and commercial infrastructure as well as technology with the aim to advance both companies’ autologous CAR-T programs towards market, pending market authorization BioNTech [...]
Genenta Demonstrated Reprogramming of the Tumor Microenvironment in GBM Patients, Paving the Way for Innovative Treatments of Solid Tumors
08/02/2024
Based on Preliminary Data from Ongoing Dose Ranging Stage of the Phase 1/2 Clinical Trial MILAN, Italy and NEW YORK, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage immuno-oncology (I/ [...]
Vandria Awarded €3.8M in Prestigious Innosuisse and Eurostars Grants to Advance Innovative Drug Programs for Age-Related Diseases of the CNS and Muscle
08/02/2024
Vandria is advancing a portfolio of mitophagy inducers to address age-related chronic diseases of the CNS, muscle, lung and liver Innosuisse grant totalling CHF 2.5M (€2.7M) to support early clinical development plan [...]
Ultimovacs ASA: Invitation to fourth quarter 2023 results webcast presentation
08/02/2024
Oslo, February 8, 2023: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology leader in novel immunotherapeutic cancer vaccines, invites to a webcast presentation of its fourth quarter 2023 results on [...]
Pharming Group to participate in February investor conferences
08/02/2024
Leiden, The Netherlands, February 8, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate in the following investor conferences in the [...]
A clearer vision for surgical robotics: CMR Surgical announces significant update to Versius
08/02/2024
A clearer vision for surgical robotics: CMR Surgical announces significant update to Versius CMR Surgical launches vLimeLite * a new imaging technology to visualise ICG, the first product launch in a series of 2024 [...]
Nicox and Kowa Enter into Agreement for NCX 470 Development and Commercialization in Japan
08/02/2024
Press Release Nicox and Kowa Enter into Agreement for NCX 470 Development and Commercialization in Japan €3 million upfront payment and a total of a further potential €27.5 million in milestones Tiered royalties on net [...]
Nicox : Contrat de licence avec la société Kowa pour le développement et la commercialisation du NCX 470 au Japon
08/02/2024
Communiqué de presse Nicox : Contrat de licence avec la société Kowa pour le développement et la commercialisation du NCX 470 au Japon Paiement initial de 3 millions d’euros et potentiels futurs paiements d’étape d’un [...]
Sana Biotechnology Announces Pricing of Upsized Public Offering
08/02/2024
SEATTLE, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (Nasdaq: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it has priced its underwritten [...]
SEQUANA MEDICAL ANNOUNCES EUR 3.0 MILLION CONVERTIBLE FINANCING FROM MAJOR SHAREHOLDERS AND AGREEMENT WITH LENDERS ON DEFERRAL OF DEBT SERVICE PAYMENTS
08/02/2024
THIS ANNOUNCEMENT IS NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD BE PROHIBITED BY APPLICABLE LAW [...]
Annual Report 2023: Strong execution across the company led to 13% organic revenue growth in GN Hearing and -8% organic revenue growth in GN Audio, while generating DKK 1.1 billion in free cash flow excl. M&A
08/02/2024
2023 highlights GN delivered DKK 18.1 billion revenue with organic revenue growth of -1%, as a result of 13% organic revenue growth in GN Hearing and -8% organic revenue growth in GN Audio Adj. EBITA of DKK 1.8 billion [...]
Building on solid FY 2023 results, Ipsen anticipates four launches in 2024
08/02/2024
Total-sales growth in FY 2023 of 6.7% at CER 1 (3.4% as reported) included strong sales from the growth platforms 2 and good contributions from the new medicines. A core operating margin of 32.0% (IFRS operating margin [...]
Après de solides résultats pour l’année 2023, Ipsen anticipe quatre lancements commerciaux en 2024.
08/02/2024
Croissance des ventes totales du Groupe en 2023 en hausse de 6,7% 1 à taux de change constant (3,4% en données publiées) tirée par les performances des plateformes de croissance 2 et la contribution des nouveaux [...]
Ibogaine By David Dardashti Improves Dosing Efficiency Through Engineering Statistics
08/02/2024
Innovative Company Utilizes Over a Hundred Variables in Treatment Protocol MIAMI, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Ibogaine By David Dardashti, a revolutionary facility dedicated to the research of ibogaine and its [...]
Tenax Therapeutics Enrolls First Patient in Phase 3 LEVEL Study Evaluating TNX-103 (Oral Levosimendan) for the Treatment of Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (PH-HFpEF)
08/02/2024
Over 40 sites (U.S. and Canada) have agreed to participate in the LEVEL study LEVEL is a randomized, controlled Phase 3 trial of 152 patients, and will recruit patients primarily from leading research centers with large [...]
Yield10 Bioscience Provides an Update on its Omega-3 Camelina Program
07/02/2024
-Prioritizes Activities to Advance Omega-3 Camelina Program in 2024 -Reports Completion of Contra Season Production of Omega-3 Camelina Seed in Chile - Company also Provides Update on Nasdaq Status - WOBURN, Mass., Feb [...]
Mydecine Innovations Group Receives Two Notice of Allowances from USPTO for its MYCO-005 and MYCO-006 Family of Compounds
07/02/2024
VANCOUVER, British Columbia, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (CSE:MYCO) (AQSE:MYIG) (OTC:MYCOF) (FSE:0NF0), a leading biotechnology company dedicated to [...]

Pages